- Home
- ACAD vs CXM Comparison
ACAD vs CXM Comparison
Compare ACAD & CXM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CXM
- Stock Information
- Founded
- ACAD 1993
- CXM 2009
- Country
- ACAD United States
- CXM United States
- Employees
- ACAD N/A
- CXM 3589
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CXM Computer Software: Prepackaged Software
- Sector
- ACAD Health Care
- CXM Technology
- Exchange
- ACAD Nasdaq
- CXM Nasdaq
- Market Cap
- ACAD 2.5B
- CXM 2.1B
- IPO Year
- ACAD 2004
- CXM 2021
- Fundamental
- Price
- ACAD $21.57
- CXM $8.43
- Analyst Decision
- ACAD Buy
- CXM Hold
- Analyst Count
- ACAD 14
- CXM 14
- Target Price
- ACAD $27.08
- CXM $9.79
- AVG Volume (30 Days)
- ACAD 3.0M
- CXM 1.0M
- Earning Date
- ACAD 05-07-2025
- CXM 06-04-2025
- Dividend Yield
- ACAD N/A
- CXM N/A
- EPS Growth
- ACAD N/A
- CXM 144.44
- EPS
- ACAD 1.37
- CXM 0.44
- Revenue
- ACAD $996,283,000.00
- CXM $796,394,000.00
- Revenue This Year
- ACAD $13.49
- CXM $4.24
- Revenue Next Year
- ACAD $10.58
- CXM $5.47
- P/E Ratio
- ACAD $15.76
- CXM $19.18
- Revenue Growth
- ACAD 22.42
- CXM 8.74
- 52 Week Low
- ACAD $13.40
- CXM $6.75
- 52 Week High
- ACAD $25.23
- CXM $11.79
- Technical
- Relative Strength Index (RSI)
- ACAD 68.70
- CXM 58.80
- Support Level
- ACAD $21.95
- CXM $7.97
- Resistance Level
- ACAD $22.62
- CXM $8.55
- Average True Range (ATR)
- ACAD 1.21
- CXM 0.18
- MACD
- ACAD 0.23
- CXM 0.02
- Stochastic Oscillator
- ACAD 56.27
- CXM 74.80
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CXM Sprinklr Inc.
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.